2,46 Mb - GuÃaSalud

More documents

Recommendations

Info

Authors and collaborations Working Group of the CPG on type 2 Diabetes Alicia Cortázar Galarza, endocrinologist, Cruecs Hospital (Bizkaia) Pablo Daza Asurmendi, general practitioner, C.S. Billabona (Gipuzkoa West District) Arritxu Etxeberria Agirre, Primary Health Care pharmacist (Gipuzkoa Est District) Patxi Ezkurra Loiola, general practitioner, C.S. Zumaia (Gipuzkoa Est District) Ignacia Idarreta Mendiola, general practitioner, C.S. Tolosa (Gipuzkoa West District) Nekane Jaio Atela, Primary Health Care pharmacist (Interior District) Mercedes Machimbarrena Minchero, nurse educator, C.S. Ntra. Sra. del Coro (Gipuzkoa) Mikel Moreno Baquedano, general practitioner, C.S. Irurtzun (Navarra) Rafael Rotaeche del Campo, general practitioner, C.S. Alza (Gipuzkoa Est District) Mª Ángeles Sola Gainza, Primary Health Care nurse, C.S. Iztieta (Gipuzkoa Est District) Itziar Villa Canibe, general practitioner, C.S. Basurto (Bilbao District) Alfredo Yoldi Arrieta, endocrinologist, Donostia Hospital (Gipuzkoa) Coordination Arritxu Etxeberria Agirre, Primary Health Care pharmacist (Gipuzkoa Est District Patxi Ezkurra Loiola, general practitioner, C.S. Zumaia (Gipuzkoa EstDistrict Rafael Rotaeche del Campo, general practitioner, C.S. Alza (Gipuzkoa Est District) Expert Collaboration Sara Artola Menéndez, general practitioner, C.S. Hereza – Leganés (Madrid) Javier Díez Espino, general practitioner, Servicio Navarro de Salud – Osasunbidea, C.S. Tafalla (Navarra) Josep Franch Nadal, general practitioner, Institut Català de la Salut, C.S. Raval-Sud (Barcelona) Sonia Gaztambide Sáenz, endocrinologist, Cruecs Hospital (Bilbao) Francisco Javier García Soidán, general practitioner, C.S. Porriño (Pontevedra) José Javier Mediavilla Bravo, general practitioner, Sanidad Castilla y León (SACYL), Pampliega Health Centre (Burgos) Carmen Suárez Alemán, Primary Health Care pharmacist, Health Service of Andalusia, D.A.P. Málaga José Antonio Vázquez García, endocrinologist, president of the Spanish Diabetes Federation (FED) CLINICAL PRACTICE GUIDELINE ON TYPE 2 DIABETES 11
Page 1: Clinical Practice Guideline on type
Page 4 and 5: A bibliographic record of this work
Page 7 and 8: Table of Contents Presentation 9 Au
Page 9 and 10: 11. Diabetic foot. Assessment, prev
Page 11: Presentation Care practice is becom
Page 15 and 16: Questions to be answered Definition
Page 17: 25. Is a diabetic nephropathy scree
Page 20 and 21: C B D The use of omega 3 fatty acid
Page 22 and 23: Insulin therapy A When an insulin t
Page 24 and 25: B B When the response to the treatm
Page 26 and 27: D C D A B D CPG Within the medical
Page 29: 2. Scope and objectives The main ai
Page 32 and 33: • Assessment of the quality of th
Page 34 and 35: The studies carried out in Spain st
Page 37 and 38: 5. Definition, natural history, cri
Page 39 and 40: 5.2.5. Low weight at birth The rela
Page 41 and 42: Green tea In a study (33) with 17,0
Page 43 and 44: 5.3. DM 2 diagnosis 5.3.1. Diagnost
Page 45 and 46: HbA 1 c could be used to diagnose d
Page 47 and 48: and certain ethnic groups (Asian, C
Page 49 and 50: 6. Diabetes prevention in patients
Page 51 and 52: An SR (72) only includes patients w
Page 53 and 54: 7. Diet and exercise The questions
Page 55 and 56: An RCT analysed the effectiveness o
Page 57 and 58: The evidence on efficacy of the dif
Page 59 and 60: Recommendations D A B B B C B D The
Page 61 and 62: 8. Glycemic control The questions t
Page 63 and 64:
4 The guidelines examined agree to
Page 65 and 66:
Its effectiveness has been recently
Page 67 and 68:
2+ Glycemic control, achieved with
Page 69 and 70:
On the other hand, the combined the
Page 71 and 72:
tion of insulin and oral diabetic d
Page 73 and 74:
glycaemia, slow or intermediate act
Page 75:
1+ There are no significant differe
Page 78 and 79:
9.1.1. Comparison of cardiovascular
Page 80 and 81:
More studies with more patients are
Page 82 and 83:
it is worth mentioning, that 19.2%
Page 84 and 85:
9.5. Treatment for high blood press
Page 86 and 87:
Regarding renal results, the slow p
Page 89 and 90:
10. Screening and treatment of micr
Page 91 and 92:
Recommendations B B The 45º non-my
Page 93 and 94:
Regarding the ARB-II, in a clinical
Page 95 and 96:
The effectiveness of antidepressive
Page 97 and 98:
Recommendations A B B Tricyclic ant
Page 99:
1+ Group psychotherapy can be more
Page 102 and 103:
11.2. Methods to assess the foot at
Page 104 and 105:
No subsequent RCTs have been found
Page 106 and 107:
These inconsistencies suggest that
Page 108 and 109:
The new dressings (hydrocolloid dre
Page 110 and 111:
Oral antibiotics Five studies were
Page 113 and 114:
12. Diabetologic education The ques
Page 115 and 116:
metabolic control (with significant
Page 117 and 118:
Recommendations A D B A B A D Peopl
Page 119 and 120:
13. Organization of the medical con
Page 121 and 122:
Initial visits Diagnosis Control vi
Page 123:
Cardiology • Coronary heart disea
Page 126 and 127:
Table 2. Levels of evidence and gra
Page 128 and 129:
Dieta 1500 kcal 126 CLINICAL PRACTI
Page 130 and 131:
128 CLINICAL PRACTICE GUIDELINES IN
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Appendix 3. Hypoglycaemic drugs Vad
Page 142 and 143:
Analogues Action profile Disposable
Page 144 and 145:
Appendix 4. Hypoglycaemia treatment
Page 146 and 147:
Appendix 5. Coronary risk tables: R
Page 148 and 149:
Appendix 7. Drugs for neuropathic p
Page 150 and 151:
Appendix 9. Education of the diabet
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Appendix 10. Assessment proposal. I
Page 158 and 159:
Appendix 11. Glossary and abbreviat
Page 160 and 161:
Abbreviations AA.CC Autonomous Comm
Page 162 and 163:
Appendix 12. Declaration of interes
Page 164 and 165:
16. Ryan EA, Imes S, Liu D, McManus
Page 166 and 167:
49. Brunner EJ, Shipley MJ, Witte D
Page 168 and 169:
80. IDF Clinical Guidelines Task Fo
Page 170 and 171:
112. Inzucchi SE. Oral antihypergly
Page 172 and 173:
142. Schwartz S, Sievers R, Strange
Page 174 and 175:
171. Marrugat J, D’Agostino R, Su
Page 176 and 177:
199. Vijan S. Hypertension in diabe
Page 178 and 179:
227. Jennings DL, Kalus JS, Coleman
Page 180 and 181:
263. Bouza C, Munoz A, Amate JM. Ef
Page 182:
P.V.P.: 6 € www.msc.es
show all

2,46 Mb - GuÃ­aSalud

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?

2,46 Mb - GuÃaSalud